Lila Sciences autonomous lab strategy

This is a bet that drug discovery will shift from people selling lab hours to integrated systems selling compressed iteration loops. Traditional CROs mostly provide expert teams that run pieces of the workflow for a client, while Lila is building autonomous labs where models propose experiments, robots run them, instruments capture results, and the system immediately uses that data to plan the next round. That structure is built to turn discovery from a handoff driven service into a high throughput feedback machine.

• A standard CRO model is still organized around specialized services, medicinal chemistry, screening, DMPK, protein work, project management. Charles River even describes discovery as a design, make, test, analyze cycle. Lila is trying to automate that entire loop inside one facility instead of passing work between teams and timelines.
  3 criver 4 criver 5 iqvia
• The closest public comparable is Recursion, which already frames automated biology as an industrial data factory, with labs processing up to 2.2 million samples per week and discovery speeds up to 3X faster than traditional industry averages. That shows the strategic logic, scale in the lab creates proprietary data, faster cycles, and more leverage from each model improvement.
  6 recursion 7 recursion 8 recursion
• This is also why the model is more capital intensive. Lila launched with autonomous lab infrastructure as a core part of the business and raised $200 million at unveiling, then announced a $235 million Series A later in 2025. Owning robots, instruments, compute, and facilities costs more than a software layer, but it also lets the company capture both the experiment revenue and the learning generated by every run.
  1 sacra 2 lila 9 lila

The companies that win this category will look less like outsourced research shops and more like scaled manufacturing systems for scientific insight. As autonomous labs get better at running whole programs instead of isolated assays, more discovery budgets will move toward platforms that can promise faster cycles, richer proprietary data, and repeatable output across many programs at once.